Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) traded at $17.85 at close of the session on Monday, 01/23/23, made a downward move of -2.99% on its previous day’s price.
Looking at the stock we see that its previous close was $18.40 and the beta (5Y monthly) reads 0.86 with the day’s price range being $17.71 – $18.71. In terms of its 52-week price range, DCPH has a high of $22.76 and a low of $6.51. The company’s stock has gained about 15.68% over that past 30 days.
Deciphera Pharmaceuticals Inc. has a market cap of $1.23 billion and is expected to release its quarterly earnings report on Feb 06, 2023 – Feb 10, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.58, with the EPS growth for the year raised at -$2.52 for 2022 and -$2.25 for next year. These figures represent 51.20% and 10.70% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $33.15 million, with a low of $31.8 million and a high of $35.8 million. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $129.96 million, or 35.20% up from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the DCPH stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 11 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 4 have rated the Deciphera Pharmaceuticals Inc. (DCPH) stock as a Hold, while 6 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 1 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -4.75% off its SMA20 and 5.99% from its 50-day simple moving average. The RSI (14) is pointing at 46.36 while the volatility over the past week is 7.59% and jumps to 7.12% over the past one month. The beta value is 0.71, while the average true range (ATR) is currently pointing at 1.40. The average price target for the stock over the next 12 months is $20.09, with the estimates having a low of $9.00 and a high of $28.00. These price ends are 49.58% and -56.86% off the current price level respectively, although investors could be excited at the prospect of a -23.25% if the DCPH share price touches on the median price of $22.00.
Let’s briefly compare Deciphera Pharmaceuticals Inc. (DCPH) stock to its peers. We find that current price change of -2.99% and 119.02% over the past 12 months for DCPH competes that of Merck & Co. Inc. (MRK), which has seen its stock price fall -0.05% in the last trading session and was 36.07% over the last one year. Another of its peers Pfizer Inc. (PFE) has dropped -0.29% previous session, and was -16.78% down over the past year, while Novan Inc. (NOVN) was also up 3.23% in the last session, while its price remained in the red at -60.98% over the same period. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.19% and 0.76%, respectively, at close of the trading.
Coming back to Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH), we note that the average 3-month trading volume was 674.66K, while that of the preceding 10-day period stands at 1.25 million. Current shares outstanding are 78.21 million.
The insiders hold 0.20% of the company’s shares while institutions hold 74.80%. The data shows that short shares as of Oct 13, 2022, stood at 7.38 million at a short ratio of 9.41. This represents a 11.05% short interest in shares outstanding on Oct 13, 2022. Shares short fall in October from the previous month at 7.46 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 8.91% up in year-to-date price movement.